Panobinostat (LBH589)

For research use only. Not for use in humans.

目录号:S1030 别名: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 953.44 现货
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Panobinostat (LBH589)发表文献234篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NYnFdWtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMVExKM7:TR?= MWGwMVQh\A>? NX;veXVjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGniZ|kzPjdyMke4OC=>
HepG2 NF7zT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfnb|AxNTFyIN88US=> M1fRWFAuPCCm MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2\Mb|I3PzB{N{i0
HT29 MnnFSpVv[3Srb36gRZN{[Xl? MVu1NOKhdk1? NIPQVZQzPC15MjDo MlzObY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg MkTxNlY4ODJ5OES=
HepG2 MVrGeY5kfGmxbjDBd5NigQ>? NEf6U|Y2OMLibl2= MVSyOE04OiCq NYjlOnhUcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh MWWyOlcxOjd6NB?=
HCC827 M13GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBTHlGPS95LkWvNVAhdk1? Mm\qO|LDqGh? MXLEUXNQ MWflcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MkPlNlY3PzV2OES=
A549  NW\TUGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXLUY9MOTBxMUWvNlAhdk1? NGLnN|c4OsLiaB?= NIG5NZhFVVOR M37meYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NWLodXZMOjZ4N{W0PFQ>
NCI-H460  NYLST2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjnVXoyOC9{MD:zNEBvVQ>? MmnZO|LDqGh? MULEUXNQ NUW3OVM6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MVGyOlY4PTR6NB?=
J89GFP MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ySG1UV8Li NXfFSJZ7TUN3ME20PU45PSEEsTCxNk43PSCwTR?= Mm[zNlY2PjN3Nki=
THP89GFP MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjNOHV4TE2VT9Mg MnXZSWM2OD1zOT6zOEDDuSB4LkSzJI5O MlzBNlY2PjN3Nki=
SK-NEP-1 NW\YPI5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\STVAvODIkgKOxNE4xKM7:TR?= MVKyOEBp NFm1WnFFVVORwrC= NXnFS2J7UUN3ME23Ok4{PCCwTR?= MXeyOlE4PjJzOR?=
G401 NIDjXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHUbHQxNjBz4pETNVAvOCEQvF2= M3nzZ|I1KGh? M3rJNWROW00EoB?= NXjqOXdwUUN3ME2xOFMvODJibl2= NX\qSWRrOjZzN{[yNVk>
SK-NEP-1 M13tcWNmdGxiVnnhZoltcXS7IFHzd4F6 MXy1NEBvVQ>? NXSxVGFyOeLCk{Sg[C=> NGf3d|RFVVORwrC= M4m5PZJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MW[yOlE4PjJzOR?=
G401 NIfQc4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2nRSlUxKG6P NVzxcWlUOeLCk{Sg[C=> NWDVdllVTE2VT9Mg NWLjZ|FuemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NE\PUpMzPjF5NkKxPS=>
SK-NEP-1 Mke0RZBweHSxc3nzJGF{e2G7 M33wVVUxNzFyMDDuUS=> NGj0cY8zPCCq NUf6PXRYTE2VT9Mg M{HnfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXSyOlE4PjJzOR?=
G401 NHHPT21CeG:ydH;zbZMhSXO|YYm= NGroZY02OC9zMECgcm0> MknBNlQhcA>? NYqxTHFUTE2VT9Mg MX\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX65O2xyOjZzN{[yNVk>
SK-NEP-1 NILQSIFHfW6ldHnvckBCe3OjeR?= NWOxfWpQPTBxMUCwJI5O NXPKN3VTOjRiaB?= MnLQSG1UV8Li NInzblZ{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MVKyOlE4PjJzOR?=
G401 M2XMSmZ2dmO2aX;uJGF{e2G7 MVq1NE8yODBibl2= MlznNlQhcA>? M2G4cWROW00EoB?= NUfVWGtDe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= NEL5VoczPjF5NkKxPS=>
SK-NEP-1 NYTXXFE4TnWwY4Tpc44hSXO|YYm= NXfmVplXPTBxMUCwJI5O NYroOHFqOjRiaB?= NYLneYRZTE2VT9Mg MYnpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> MWiyOlE4PjJzOR?=
G401 MoHaSpVv[3Srb36gRZN{[Xl? MYK1NE8yODBibl2= M3zmVFI1KGh? M1X1NGROW00EoB?= Mkn0bY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> MYOyOlE4PjJzOR?=
RPMI 8226 M3TSSGNmdGxiU4Xyeol3[WxiQYPzZZk> M4PtdFIwPC94IH7N MYG0PQKBkWh? M{XnS4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NVr4e2VbOjZyMECyPVI>
OPM2 NW\6XotTS2WubDDTeZJ3cX[jbDDBd5NigQ>? MUOyM|QwPiCwTR?= M{\Y[|Q56oDLaB?= M{m5[Ilv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? M1\JUVI3ODByMkmy
U266 M3P0bWNmdGxiU4Xyeol3[WxiQYPzZZk> NH\RbZAzNzRxNjDuUS=> MVy0PQKBkWh? M4ixSIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NYXVbZZYOjZyMECyPVI>
H929 NYqzdHNnS2WubDDTeZJ3cX[jbDDBd5NigQ>? MUeyM|QwPiCwTR?= MkDWOFjjiImq M{ftRYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NWHnbWZKOjZyMECyPVI>
RPMI 8226  MX3BdI9xfG:|aYOgRZN{[Xl? M1rIZ|TjiImwTR?= MWqyOE81QCCq NGjmcpJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MmS1NlYxODB{OUK=
HCC827 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ZRnFqOTBibl2= MV:0PEBp NFnHXpJFVVOR NGPUNmpmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= MWqyOVk1PDZzNx?=
NCI-H23 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHwNVAhdk1? M{DvZ|Q5KGh? MVrEUXNQ MX\lcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? NFHCbIYzPTl2NE[xOy=>
AML3 MnfsSpVv[3Srb36gRZN{[Xl? M4XoTlAuOSEQvF2= M1;KNVI1yqCq M4\ES4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGnJW5czPTZzMkm0NS=>
ML-1 NUji[ld[TnWwY4Tpc44hSXO|YYm= M4\peFAuOSEQvF2= Mnr6NlTDqGh? NYS4RYJEcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NU\DUoI3OjV4MUK5OFE>
RPMI-8226vr10  Mm\RSpVv[3Srb36gRZN{[Xl? M1HIeVAuOSEQvF2= MUWyOOKhcA>? MknXbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGPuO5ozPTZzMkm0NS=>
ML-1 MkOzSpVv[3Srb36gRZN{[Xl? MnzMNUDPxE1? NF3ESngzPMLiaB?= NWDBPXgzcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> MmDVNlU3OTJ7NEG=
RPMI-8226vr10  Mo\kSpVv[3Srb36gRZN{[Xl? M3zOdlEh|ryP M3mwdVI1yqCq NULkS2tncW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>? NGfQfFczPTZzMkm0NS=>
SK-N-BE (2) NY\NVHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInCb24zPOLCiXi= NUSwfpRzUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N NGfxbGIzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK M2TPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLwSGczPOLCiXi= Ml7nTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NFfaRWEzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN M1HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\5NlTjiImq MYXJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P M2jMRlI2OzB6OUG2
SK-N-AS MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki4NlTjiImq NUHSfJplUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= NUDZc|duOjV|MEi5NVY>
SK-N-DZ M{XFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSyOQKBkWh? MXjJR|UxRTF5LkJihKnDueLCiUCuOEBvVQ>? NInkWYkzPTNyOEmxOi=>
Caki-1 NVLvTIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHnNVAwOjVxNUCgcm0> NXTJZYp7PDhiaB?= NV6xOFVNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NYLj[XJ1OjV{N{mxPVE>
ACHN NX;CbYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3zbpMyOC9{NT:1NEBvVQ>? NHLZUWo1QCCq MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? M1;3WFI2Ojd7MUmx
769-P NHnKWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfxbZoyOC9{NT:1NEBvVQ>? NIHqR2Q1QCCq NGXNOVZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MXOyOVI4QTF7MR?=
786-O  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCPFExNzJ3L{WwJI5O NW\oN|ZbPDhiaB?= NW\XbZZzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NVG3UndDOjV{N{mxPVE>
Caki-1 MXfBdI9xfG:|aYOgRZN{[Xl? MmDLOVAhdk1? NEDnWWo1QCCq NFjqeYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M1\4RVI2Ojd7MUmx
ACHN NU\jTHdLSXCxcITvd4l{KEG|c3H5 MmD3OVAhdk1? MnrROFghcA>? M33iNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MW[yOVI4QTF7MR?=
769-P MVvBdI9xfG:|aYOgRZN{[Xl? M2fHNVUxKG6P MUi0PEBp MWDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? M2HsflI2Ojd7MUmx
786-O  NHThSVBCeG:ydH;zbZMhSXO|YYm= MWe1NEBvVQ>? NXmwbphOPDhiaB?= NFrUOWJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NIS2RokzPTJ5OUG5NS=>
Caki-1 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6yOU82OCCwTR?= MVy0PEBp MU\EUXNQ M1rHOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= MVqyOVE4PjN3NB?=
ACHN M{TBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\rSGQzPS93MDDuUS=> NYrXUpFiPDhiaB?= NFm3emRFVVOR M2XEcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NYjiTWJXOjVzN{[zOVQ>
769-P NWfsfo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0S28zPS93MDDuUS=> MVu0PEBp M{f2bGROW09? MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MUWyOVE4PjN3NB?=
Caki-1 M4PSbGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MkPUOVAhdk1? M1fq[VcuOTRiZB?= NWjzN5p5TE2VTx?= NWfSdpQ1e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MV[yOVE4PjN3NB?=
ACHN MXfDc4xwdnliRn;ycYF1cW:wIFHzd4F6 M2TDVFUxKG6P MoHRO{0yPCCm NF30NXhFVVOR MVjzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M{jZVFI2OTd4M{W0
769-P MUTDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NV7xWnROPTBibl2= Ml\LO{0yPCCm MXjEUXNQ NH7iUoN{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MVGyOVE4PjN3NB?=
Caki-1 M{f0ZWFxd3C2b4Ppd{BCe3OjeR?= NFn1WI02OCCwTR?= MVS0PEBp M1rRdmROW09? NVn2SW0xcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYCyOVE4PjN3NB?=
ACHN Mnr3RZBweHSxc3nzJGF{e2G7 MUm1NEBvVQ>? M3LPeVQ5KGh? M{DqfmROW09? Ml3VbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NX;IbnFzOjVzN{[zOVQ>
769-P NI\v[HJCeG:ydH;zbZMhSXO|YYm= NEfr[GU2OCCwTR?= NYLKZ5lLPDhiaB?= NFX0NFZFVVOR MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXiyOVE4PjN3NB?=
MDA-MB-231 MXHNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> NVzUOoJGOTEEoH7N MXezxsBl MkTLSG1UVw>? NXXIe2ky[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MYWyOFgyODR7Nx?=
BT-549 M{PjfW1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NYfHUZpvOTEEoH7N M2jTTlPDqGR? NUCwRm5RTE2VTx?= NIXtbVlidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= MVSyOFgyODR7Nx?=
MCF-7  NIHjVG5Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M3HOeFExyqCwTR?= NGrybJU{yqCm M1;RXWROW09? NYrRXIVW[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M3vNRlI1QDFyNEm3
MCF-7 MWXGeY5kfGmxbjDBd5NigQ>? NWHqW20zPS13MDDuUS=> NFfte28zPCCq NH24XHJFVVOR NUjvfZVuemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? NG\2fmUzPDN4NkSwOy=>
CTS MoDORZBweHSxc3nzJGF{e2G7 MXmw5qCUPDBibl5CpC=> M1zPZlQ5KGh? M4W1S4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWeyOFI1PDR{OR?=
OCI-AML3  Mn;aRZBweHSxc3nzJGF{e2G7 NYmyVYxlOOLCk{SwJI5OyqB? MXW0PEBp M1\mTYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWOyOFI1PDR{OR?=
U937 MX\BdI9xfG:|aYOgRZN{[Xl? MUWw5qCUPDBibl5CpC=> NH34UJA1QCCq MVXpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXHuNZdUOjR{NES0Nlk>
PC3 NGXJWYtCeG:ydH;zbZMhSXO|YYm= M{LxNVAuOTByIH7N MXiyOE81QCCq MULpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NW\0[HQxOjRzNkOyN|A>
PC3-AR NYTkUZBySXCxcITvd4l{KEG|c3H5 NIHHNHYxNTFyMDDuUS=> MkKyNlQwPDhiaB?= M{nvbIlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmPqNlQyPjN{M{C=
PC3 NXfBUVB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMVExOCCwTR?= MlvkNlQwPDhiaB?= M{naOIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? MWGyOFE3OzJ|MB?=
PC3-AR MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILYNlAxNTFyMDDuUS=> NFK0NJIzPC92ODDo NY\3WI9NcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|JOKHCqYYPl NEn0[pUzPDF4M{KzNC=>
PC3 MX\GeY5kfGmxbjDBd5NigQ>? MYCwMVExOCCwTR?= NFOxXYQzPCCq MVvzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= Mn\GNlQyPjN{M{C=
PC3-AR MVLGeY5kfGmxbjDBd5NigQ>? MkToNE0yODBibl2= MmLtNlQhcA>? NY\EV4tue3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> M3PDXlI1OTZ|MkOw
OS-RC-2 NYnmc21OS2WubDDWbYFjcWyrdImgRZN{[Xl? M2f6WVAuOTByMDDuUS=> M4LybFI1NzR6L{eyJIg> NHzwZVVFVVOR M4XsboRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWPZOVNIOjRzNES3N|c>
OS-RC-2 M2XGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnoZWhsPTBibl2= M2TON|Q5KGh? M1HVZmROW09? MXXpcoR2[2W|IFeyM20h[XK{ZYP0 MofXNlQyPDR5M{e=
OS-RC-2 NXq4OoM{SXCxcITvd4l{KEG|c3H5 NGTwU2I2OCCwTR?= NWXCUJFnPDhiaB?= NGnUR|hFVVOR MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3vCbFI1OTR2N{O3
SK-N-AS NGjYSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSw5qCUQDBibl2= MormOFghcA>? NH;IWnFKSzVyPUK3MlQhdk1? M1XLc|I1ODl6N{m5
SK-N-DZ NHXKfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[wSXBtOOLCk{iwJI5O Mn\4OFghcA>? Ml;XTWM2OD1{MT65JI5O MVSyOFA6QDd7OR?=
SK-N-SH MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWw5qCUQDBibl2= Mk[1OFghcA>? MYTJR|UxRTd{LkOgcm0> NGGyPGgzPDB7OEe5PS=>
SK-N-BE MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TKT|DjiJN6MDDuUS=> MkHBOFghcA>? NVmwNFdpUUN3ME23OU41KG6P MmLRNlQxQTh5OUm=
SK-N-AS NG\X[YtCeG:ydH;zbZMhSXO|YYm= NYLYd4FrOOLCk{iwJI5O NX\NNWVYPDhiaB?= Mn:4dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NHfvc5gzPDB7OEe5PS=>
SK-N-DZ NUDHOHE{SXCxcITvd4l{KEG|c3H5 NUHxZ21NOOLCk{iwJI5O M{jQflQ5KGh? MlSzdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MX6yOFA6QDd7OR?=
SK-N-SH NG\sdXNCeG:ydH;zbZMhSXO|YYm= MVGw5qCUPDBibl2= NX7pdGhRPDhiaB?= Mk\FdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u Mn\qNlQxQTh5OUm=
SK-N-BE M33rdmFxd3C2b4Ppd{BCe3OjeR?= MkHWNQKBmzRyIH7N MWO0PEBp MU\wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= Mn7RNlQxQTh5OUm=
SK-N-AS MoDhSpVv[3Srb36gRZN{[Xl? NXrUO3pZOOLCk{iwJI5O NIjGcIs1QCCq NVn6XIdocW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MViyOFA6QDd7OR?=
SK-N-DZ MYnGeY5kfGmxbjDBd5NigQ>? MV6w5qCUQDBibl2= NWSzPYdlPDhiaB?= M3\FOIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> M3nVZVI1ODl6N{m5
SK-N-SH MVzGeY5kfGmxbjDBd5NigQ>? NVrETYhHOOLCk{SwJI5O MofXOFghcA>? NXnkNYVKcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NYH5[GViOjRyOUi3PVk>
SK-N-BE M2jMcWZ2dmO2aX;uJGF{e2G7 M1;vclDjiJN2MDDuUS=> NEPUOYU1QCCq MYTpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M4nhdlI1ODl6N{m5
HCC-LM3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL4eYcyNTFyMECgcm0> NFzWc2EzPC92OD:3NkBp MX\EUXNQ M3;JN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3HSeFI1ODl|OUW2
HepG2 M{HzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XabVEuOTByMDDuUS=> NGfaRoQzPC92OD:3NkBp MXHEUXNQ MoS3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF7h[m4zPDB7M{m1Oi=>
SMMC-7721 NECzb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL4OIY3OS1zMECwJI5O MXiyOE81QC95MjDo NXfGU4k1TE2VTx?= NIK4OIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NV:4WWJ7OjRyOUO5OVY>
HCC-LM3 NHjMdJhCeG:ydH;zbZMhSXO|YYm= M3ftTVUxKG6P NGLhW2Q1QCCq MYXEUXNQ NXvJbHk1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NEn2XYgzPDB7M{m1Oi=>
HepG2 MoHkRZBweHSxc3nzJGF{e2G7 MnLXOVAhdk1? NHThbFc1QCCq M3jac2ROW09? M3\ke4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M4fTbFI1ODl|OUW2
SMMC-7721 NF7RW|NCeG:ydH;zbZMhSXO|YYm= M37kfVUxKG6P NVPFTVk5PDhiaB?= MYjEUXNQ MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NWnpXG1DOjRyOUO5OVY>
HCC-LM3 NIPzWIlHfW6ldHnvckBCe3OjeR?= MV21NE8yODBibl2= MYGyOEBp NXPvWnQ{TE2VTx?= NGrwNGxl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NHTMc4QzPDB7M{m1Oi=>
HepG2 M{mxcWZ2dmO2aX;uJGF{e2G7 Mn7COVAwOTByIH7N NXnSc4Z{OjRiaB?= Mk[ySG1UVw>? MlWx[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= M2Xhd|I1ODl|OUW2
SMMC-7721 M4TJc2Z2dmO2aX;uJGF{e2G7 MXq1NE8yODBibl2= MV6yOEBp MUTEUXNQ NH;JU2Jl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NIX4O3IzPDB7M{m1Oi=>
HCC-LM3 MojSSpVv[3Srb36gRZN{[Xl? M3HoWVUxNzFyMDDuUS=> NVS4TIFMOjRiaB?= NUewco56TE2VTx?= NFq0PXFld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MX[yOFA6Ozl3Nh?=
HepG2 NEHrSYFHfW6ldHnvckBCe3OjeR?= MXG1NE8yODBibl2= MV6yOEBp MVfEUXNQ M1rUcoRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NF3FTGQzPDB7M{m1Oi=>
SMMC-7721 NHHpbm5HfW6ldHnvckBCe3OjeR?= Ml\tOVAwOTByIH7N M2PVRVI1KGh? MnezSG1UVw>? NXr0VnZL\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NXPuTWRxOjRyOUO5OVY>
FaDu NFHmb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xNFDjiIWwTR?= NF7SXGc5NzFyL{GyJIg> M3r0VYRqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG|ZR?= MWmyOFAzPjR6Mh?=
FaDu NXnHNplNTnWwY4Tpc44hSXO|YYm= M3TufFExOOLChX7N NHSwSoozNzRxOD:xNkBp NVzvNZRMcW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36= M{\qfFI1ODJ4NEiy
PC-3  Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKwMVExKM7:TR?= MYWyOE81QC95MjDo M1;aT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUPOcpVIOjN7OUGyNVY>
LNCaP M1;uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKwMVUh|ryP MmHyNlQwPDhxN{KgbC=> NEf4XHVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV2yN|k6OTJzNh?=
RWPE-1  NHzvSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki1NE0zOCEQvF2= MYCyOE81QC95MjDo M1THcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnLGNlM6QTF{MU[=
Capan-1 NIjQTXhHfW6ldHnvckBCe3OjeR?= MoTlNlUwPTBxMUCwJI5O MojVPE8zPC92ODDo NIXneI9FVVOR MVTkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MYeyN|kzOjh6Nh?=
L3.6pl MXjGeY5kfGmxbjDBd5NigQ>? NF\sc|kzPS93MD:xNFAhdk1? Mn\pPE8zPC92ODDo NWX6e|BjTE2VTx?= Mlj3[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NIPIcmczOzl{Mki4Oi=>
CFPAC-1  MlG0SpVv[3Srb36gRZN{[Xl? M3vZZlI2NzVyL{GwNEBvVQ>? MnS4PE8zPC92ODDo M1Plc2ROW09? NIXBVGxld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n MUmyN|kzOjh6Nh?=
Capan-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnYcVQzPS93MD:xNFAhdk1? MkG0OFghcA>? MVXEUXNQ NHO0Tldz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFH4cI0zOzl{Mki4Oi=>
L3.6pl MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL0NlUwPTBxMUCwJI5O MXy0PEBp NFnRWnhFVVOR NFrrV2Fz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX7R[2M2OjN7MkK4PFY>
CFPAC-1  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLKUGYzPS93MD:xNFAhdk1? MkfJOFghcA>? NUfSXlZETE2VTx?= NUe1SmVWemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3vyNFI{QTJ{OEi2
Capan-1 M4TRPWFxd3C2b4Ppd{BCe3OjeR?= NYTWR2RoOjVxNUCvNVAxKG6P MWW0PEBp MUTEUXNQ NF\CeZVqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnHSNlM6OjJ6OE[=
L3.6pl NIrKVplCeG:ydH;zbZMhSXO|YYm= MoPnNlUwPTBxMUCwJI5O NIf4RVI1QCCq NWr2SHllTE2VTx?= NV3DO2tqcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4TsRlI{QTJ{OEi2
CFPAC-1  M3PhOWFxd3C2b4Ppd{BCe3OjeR?= NXflW3VNOjVxNUCvNVAxKG6P NFPXdWk1QCCq MVnEUXNQ NIrRTIpqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXXs[29UOjN7MkK4PFY>
HN22 NGmzSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPrRnlXOC1{MDDuUS=> M3H4clI1NzR6IHi= MXzEUXNQ NILyXFhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NIDoTY0zOzh5N{KzOS=>
HSC4  M3XQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPYb5RpOC1{MDDuUS=> NHvjSFUzPC92ODDo NGDtRnVFVVOR MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MYmyN|g4PzJ|NR?=
HN22 MoXlRZBweHSxc3nzJGF{e2G7 MYGwMVIxKG6P NETydog1QCCq NHTXXnlFVVOR NXG0UXh5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX;vXVVnOjN6N{eyN|U>
HSC4  M1\5bGFxd3C2b4Ppd{BCe3OjeR?= MUSwMVIxKG6P NX62[29KPDhiaB?= MV3EUXNQ MknObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3LpPFI{QDd5MkO1
HN22 NUnXb49TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\OZ4kxNTJyIH7N NXnuRWRrPDhiaB?= MoHhSG1UVw>? NEXWW5FqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> NU\6Z4hxOjN6N{eyN|U>
HSC4  M3jGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCyUI9HOC1{MDDuUS=> Mlu3OFghcA>? NXTudHpzTE2VTx?= MkXRbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg NGn2d2szOzh5N{KzOS=>
HN22 MXzGeY5kfGmxbjDBd5NigQ>? NUPJUFdDOC1{MDDuUS=> MV:0PEBp MYrEUXNQ NF73bIV{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NXjB[2dDOjN6N{eyN|U>
HSC4  M2HB[2Z2dmO2aX;uJGF{e2G7 M1;hWFAuOjBibl2= NV2xOZlPPDhiaB?= MUfEUXNQ MVPzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NVTmRWRSOjN6N{eyN|U>
Cal62 NHXKSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;2PWN4UUN3ME2zN{DDuSB2IH7N M1H0U|I{QDJ2ME[0
Hth7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF3INMxJFIhdk1? NIWwNVUzOzh{NEC2OC=>
Hth83 M1rBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS1TWM2OD1|NDFCtUA2KG6P MWeyN|gzPDB4NB?=
C643 NH[1SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTdzINMxJFExKG6P MUGyN|gzPDB4NB?=
SW1736 M2T5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\OZ21WUUN3ME2zOUDDuSB6IH7N Mny2NlM5OjRyNkS=
T241 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33PJV2UUN3ME22OUDDuSB5IH7N MVeyN|gzPDB4NB?=
T351 M4TKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVyINMxJFExKG6P NXnBcohzOjN6MkSwOlQ>
BHP2-7 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH5TWM2OD1|NzFCtUA3KG6P NELlfY8zOzh{NEC2OC=>
T238 NGjVd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j2VmlEPTB;MTy1NFAhyrFiMkCwJI5O NWW0Z5hpOjN6MkSwOlQ>
HCT8 M1ro[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LzTVczKGh? NXexfWdzTE2VTx?= MVTJR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? NXfTNVI6OjN{OUmzPFg>
H630 NV\nXIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp Ml;3SG1UVw>? MmnoTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? M1vUfVI{Ojl7M{i4
cH630 5-FU-res MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:3NkBp M{PSSmROW09? NVTPPII4UUN3ME2xOU426oDLwsJihKkyNjJibl2= M1\iWFI{Ojl7M{i4
HCT116 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HP[FczKGh? MVnEUXNQ M2TzZWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P NXPEe5VzOjN{OUmzPFg>
HCT116 p53−/− M4LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfxO|IhcA>? MVvEUXNQ MWjJR|UxRThwNvMAjeKy6oDLMT63JI5O M1;POlI{Ojl7M{i4
dHCT116 p21−/− MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTk[5hpPzJiaB?= NIfl[3dFVVOR NHvxWohKSzVyPUWuPgKBkcLz4pEJNU4{KG6P NH\CNYUzOzJ7OUO4PC=>
HT29 NW\jcGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjBO|IhcA>? NVnSdm1ETE2VTx?= NG\QUFdKSzVyPUG2MlPjiIoEsfMAjVIvOyCwTR?= Mn7BNlMzQTl|OEi=
LoVo MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pt[|czKGh? MXTEUXNQ M3S0W2lEPTB;NT6x5qCKyrIkgJmwMlYhdk1? NUPPe5N5OjN{OUmzPFg>
RKO NXmxV4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2izZ|czKGh? MnzXSG1UVw>? NIfkZ2tKSzVyPUeuPgKBkcLz4pEJNk4zKG6P NVWwOJNDOjN{OUmzPFg>
SW480 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXhO|IhcA>? NIfj[2dFVVOR M1jweWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P Mlm2NlMzQTl|OEi=
eSW620 NYnKe|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vpdVczKGh? MX;EUXNQ MmPuTWM2OD17LkJihKnDueLCiUKuNUBvVQ>? MXGyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
储存条件 粉状
溶于溶剂
别名 NVP-LBH589

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Not yet recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio May 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID